INSIGHTS ON CLINICAL TRIAL PARTNERING
-
![IQVIA IRT SAVE]( "Benefit From Enhanced Power And Intelligence")
Benefit From Enhanced Power And IntelligenceFind a supply automation value engine with intelligent automation and algorithms to analyze drug supply data and automatically adjust delivery quantities to each site based on data available in IRT.
-
![GettyImages-1219551222-Patient-Person-Recruitment-Select]( "Dysfunctions Of Clinical Trial Vendor Selection And Overcoming Them")
Dysfunctions Of Clinical Trial Vendor Selection And Overcoming ThemVendor selection often fails due to five common dysfunctions. Identifying and addressing them early improves alignment, trust, and trial performance—avoiding costly delays.
-
![GettyImages-1311977468 site payments]( "2025 Clinical Trial Payment Tax Implications Explained")
2025 Clinical Trial Payment Tax Implications ExplainedFlat-rate clinical trial payments are often taxable in the U.S., while reimbursements are not. Unclear tax rules can impact participant trust, site communication, and trial retention.
-
![GettyImages-2163190867-hospital-doctor-administrator-discussion]( "Site Management Support To Investigational Sites")
Site Management Support To Investigational SitesRare disease trials demand specialized site support. Explore how tailored site management practices can improve consistency, data quality, and patient engagement in complex clinical studies.
-
Why Use Scorecards To Make Vendor Selection Decisions10/21/2025
Scorecards enable structured, unbiased vendor selection by transforming complex clinical trial decisions into transparent, data-driven evaluations — ensuring operational excellence and regulatory compliance.
-
The Founder Behind The Platform7/1/2025
Learn about the founding and mission of ClinAI, a groundbreaking platform that leverages automation and analytics to enhance vendor selection and management.
-
A Turnkey Solution For Clinical Trials In Australia6/16/2025
This presentation is centered on Australia's unique value proposition in the global research landscape, emphasizing its ability to deliver high-quality trials with speed and efficiency.
-
Patient Centric Clinical Trials: Why Transportation Is A Timeline Risk2/24/2026
Address transportation barriers to reduce protocol deviations and data gaps. Strategies that lower travel burden protect study timelines and improve visit adherence for better trial outcomes.
-
How To Select The Right Bioanalysis CRO For Your Program11/3/2025
The right bioanalysis CRO accelerates progress, while the wrong one can derail outcomes. When every provider claims speed and credibility, how do you confidently choose the right partner?
CLINICAL TRIAL PARTNERING SOLUTIONS
-
![GettyImages-1971327276 doctor patient]( "Balancing The Scales: The Strategic Role Of Stipends In Trial Success")
Traditional clinical trial models can create financial burden by neglecting participant needs – but effective use of stipends can allow participants to fully engage without financial worries.
-
![GettyImages-681726866 patient, payment, reimbursement]( "Why Fee-Free Trial Participant Payments Always Pay Off")
Remove the administrative burden of clinical trials for patients while ensuring compliance and offering global accessibility.
-
![oncology-trials-experts-GettyImages-2181815223]( "Oncology Clinical Trial Experts For Complex Trial Design")
Complex oncology trials require deep science, regulatory expertise, and coordination. See how integrated teams and adaptive designs speed startup, protect patients, and scale.
-
![iqvia-globe]( "IQVIA Investigator Site Portal")
IQVIA Technologies’ Investigator Site Portal (formerly DrugDev) offers sponsors, CROs, and sites the ability to manage trials easily and efficiently, from beginning to end, by enabling users to communicate effortlessly with sites, design and execute goals, and provide reporting, trial metrics, and much more.
-
![GettyImages-2182383108-ADC-manufacturing-scientist]( "Purpose-Built For ADC Development")
Antibody-drug conjugates (ADCs) are transforming cancer care by combining precision antibody targeting with potent payloads to improve patient outcomes.
